James Mahon

MidKent College — United Kingdom

Medicine · Health Sciences

15h-index778citations55works0.62yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Diabetes Management and Research(9), Diabetes Treatment and Management(6), Hyperglycemia and glycemic control in critically ill and hospitalized patients(5), Health Systems, Economic Evaluations, Quality of Life(4), Pharmaceutical Economics and Policy(3)

Publications55 total

Clinical equivalence and non-inferiority within health technology assessment
The European Journal of Health Economics·2025· 2 cited
HTA300 Reappraisal Following the Loss of Medicine Patent in HTA Guidelines
Value in Health·2024Open Access
Lenvatinib plus pembrolizumab for untreated advanced renal cell carcinoma: a systematic review and cost-effectiveness analysis
Health Technology Assessment·2024· 1 citedOpen Access
Estimating the cost due to resistance against antiretroviral therapies in individuals with HIV: Perspective of the Kingdom of Saudi Arabia
IJID Regions·2024Open Access
Estimation of the health economic benefit of widening pulmonary rehabilitation uptake and completion
Chronic Respiratory Disease·2024Open Access
Correction: Onasemnogene Abeparvovec for Treating Pre-symptomatic Spinal Muscular Atrophy: An External Assessment Group Perspective of the Partial Review of NICE Highly Specialised Technology Evaluation 15
PharmacoEconomics - Open·2023Open Access
Onasemnogene Abeparvovec for Treating Pre-symptomatic Spinal Muscular Atrophy: An External Assessment Group Perspective of the Partial Review of NICE Highly Specialised Technology Evaluation 15
PharmacoEconomics - Open·2023· 9 citedOpen Access
Pegcetacoplan for Treating Paroxysmal Nocturnal Haemoglobinuria: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
PharmacoEconomics - Open·2023· 1 citedOpen Access
Trastuzumab Deruxtecan for Treating HER2-Positive Unresectable or Metastatic Breast Cancer After Two or More Anti-HER2 Therapies: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
PharmacoEconomics - Open·2023· 2 citedOpen Access
Diagnostic accuracy and clinical impact of MRI-based technologies for patients with non-alcoholic fatty liver disease: systematic review and economic evaluation
Health Technology Assessment·2023· 6 citedOpen Access
A systematic review of cost-utility analyses of screening methods in latent tuberculosis infection in high-risk populations
BMC Pulmonary Medicine·2022· 18 citedOpen Access
PRO61 Health-Related Quality of Life (HRQOL) and Healthcare Resource Use (HCRU) Associated with the Treatment of Pompe Disease (PD): Targeted Literature Reviews
Value in Health·2021Open Access
PMU46 Impact of Assumptions Used in Cost-Effectiveness Analysis (CEA) on the Outcomes of CEA across Disease Areas
Value in Health·2021Open Access
Improving management of glycaemic control in people with T2DM in primary care: estimation of the impact on the clinical complications and associated costs
BMC Health Services Research·2020· 8 citedOpen Access
Prophylactic removal of impacted mandibular third molars: a systematic review and economic evaluation
Health Technology Assessment·2020· 61 citedOpen Access
Encorafenib with Binimetinib for the Treatment of Patients with BRAF V600 Mutation-Positive Unresectable or Metastatic Melanoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
PharmacoEconomics - Open·2020· 6 citedOpen Access
Lead-I ECG for detecting atrial fibrillation in patients with an irregular pulse using single time point testing: a systematic review and economic evaluation
Health Technology Assessment·2020· 23 citedOpen Access
Lead-I ECG for detecting atrial fibrillation in patients attending primary care with an irregular pulse using single-time point testing: A systematic review and economic evaluation
PLoS ONE·2019· 26 citedOpen Access
Improving management of glycaemic control in people with T2DM in Primary Care: estimation of the impact on the clinical complications and associated costs
2019Open Access
A review of the NG17 recommendations for the use of basal insulin in type 1 diabetes
Diabetic Medicine·2019· 6 citedOpen Access
page 1 of 3Next →

Frequent Co-authors

Angela Boland(18), Sophie Beale(17), Eleanor Kotas(17), Y Dündar(16), Nigel Fleeman(15), Marty Richardson(10), J Greenhalgh(10), Sarah J Nevitt(10), Kerry Dwan(9), Nick Hex(8), Vickie Bates(7), Laura Ellis(7), Ben Nj Shaw(7), Rachel Houten(7), Rui Duarte(6), Joanne McEntee(6), Marty Chaplin(6), R Dickson(6), Julie Glanville(4), Hannah Wood(4)